Human Immunology Biosciences, Inc.

One year after Biogen bought the CD38-targeting antibody felzartamab in its acquisition of Human Immunology Biosciences (HI-Bio), the company has initiated two Phase III studies in two different areas

CEO Christopher Viehbacher has been straightforward about Biogen’s challenges since taking the helm in November 2022, and that did not change as the company reported its fourth-quarter and full-year 2

In what observers are calling a sensible deal for both sides, Stoke Therapeutics and Biogen revealed on 18 February that they will collaborate on development and commercialization of Stoke’s antisense

CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversif